Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Drug Profile

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen; Z-Endoxifen Hydrochloride

Latest Information Update: 06 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders
  • Phase II Breast cancer
  • Phase I Fibroma; Gynaecological cancer

Most Recent Events

  • 23 Mar 2020 Phase-III clinical trials in Bipolar disorders (Treatment-experienced) in USA (PO) (NCT04315792)
  • 30 Apr 2019 Intas Pharmaceuticals completes a phase III trial in Bipolar disorders in India (PO) (CTRI2017-07-009163)
  • 23 Apr 2019 National Cancer Institute suspends phase I trial in Breast cancer (Neoadjuvant therapy, Metastatic disease) in USA (Topical) (NCT03317405)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top